Loader

Pathways

PathWhiz ID Pathway Meta Data

PW063744

Pw063744 View Pathway
drug action

Clocinizine H1-Antihistamine Action

Homo sapiens
Clocinizine is a first-generation diphenylmethylpiperazine H1-antihistamine. H1-antihistamines interfere with the agonist action of histamine at the H1 receptor and are administered to attenuate inflammatory process in order to treat conditions such as allergic rhinitis, allergic conjunctivitis, and urticaria. Reducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression of pro-inflammatory cytokines, cell adhesion molecules, and chemotactic factors. Furthermore, lowering calcium ion concentration leads to increased mast cell stability which reduces further histamine release. First-generation antihistamines readily cross the blood-brain barrier and cause sedation and other adverse central nervous system (CNS) effects (e.g. nervousness and insomnia). Second-generation antihistamines are more selective for H1-receptors of the peripheral nervous system (PNS) and do not cross the blood-brain barrier. Consequently, these newer drugs elicit fewer adverse drug reactions.

PW127779

Pw127779 View Pathway
drug action

Clocortolone Action Pathway

Homo sapiens
Clocortolone, brand name Cloderm, is a corticosteroid used as a topical cream to treat inflammatory and pruritic dermatoses of the scalp. Clocortolone is a moderate potency topical corticosteroid that should not be used with occlusive dressings. As this drug is a glucocorticoid, its mechanism of action is that of the glucocorticoid response element (GRE) influencing COX-2/prostaglandin G/H synthase 2 suppression and lipocortin/annexin induction. By binding to the glucocorticoid receptor, it influences transcription factors AP-1 and NF-kB to block the transcription of COX-2/prostaglandin G/H synthase 2 which reduces the amount of prostanoids being produced from arachidonic acid. Prostanoids such as PGI2 and thromboxane A2 influence the effects of inflammation through vasoconstriction/dilation, pain sensitivity, and platelet aggregation. Clocortolone also affects the promoter of annexin-1, an important inflammatory protein as it affects leukocytes and blocks phospholipase A2 which reduces the amount of arachidonic acid being cleaved from the phospholipid bilayer. Reducing the amount of arachidonic acid formed further decreases the concentrations of prostanoids mentioned calming inflammation.

PW144943

Pw144943 View Pathway
drug action

Clocortolone Drug Metabolism Action Pathway

Homo sapiens

PW127900

Pw127900 View Pathway
drug action

Clodronic Acid Action Pathway

Homo sapiens
Clodronic acid is a bisphosphonate used for the treatment of osteoporosis in women experiencing menopause, hypercalcemia malignancy and osteolysis. Travelling into the bone it binds to hydroxyapatite, osteoclast break down the bone releasing the bisphosphonate. Bisphosphonate is then consumed by the osteoclast by endocytosis and disrupts their mechanism of breaking down the bone. Usually administered intravenously, it is not metabolized and is eliminated via the urine unchanged. Caution should be taken as severe overdoses can cause kidney failure, liver damage and render the patient unconscious. It can be managed through monitoring as hypocalcemia can present itself prior to the overdose, and specializing care via the administration of electrolytes.

PW132308

Pw132308 View Pathway
metabolic

Clodronic acid Drug Metabolism

Homo sapiens
Clodronic acid is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Clodronic acid passes through the liver and is then excreted from the body mainly through the kidney.

PW144832

Pw144832 View Pathway
drug action

Clodronic acid Drug Metabolism Action Pathway

Homo sapiens

PW128094

Pw128094 View Pathway
drug action

Clofarabine Action Pathway

Homo sapiens
Clofarabine is a purine (adenosine) antimetabolite, it is a drug used as an antineoplastic in the treatment of pediatric patients with relapsed or refractory acute lymphocytic leukemia. This molecule differs from the other purine analogs by chlorine in the purine ring and fluorine in the ribose moiety. This drug enters the cell and is metabolized to the active 5'-monophosphate metabolite by the enzyme deoxycytidine kinase. It is also metabolized in the 5'-triphosphate metabolite by mono- and di-phospho kinase. The tri-phosphate metabolite inhibits DNA synthesis through an inhibitory action on ribonucleotide reductase, and by terminating DNA elongation and inhibiting repair through competitive inhibition of DNA polymerases. Those inhibitions lead to the depletion of the intracellular deoxynucleotide triphosphate pool thereby intensifying the effectiveness of DNA synthesis inhibition. Clofarabine 5'-triphosphate also disrupts the integrity of the mitochondrial membrane, leading to the release of the pro-apoptotic mitochondrial proteins, cytochrome C, and apoptosis-inducing factor. All of the cited inhibitions and activities of this drug lead to cell death (apoptosis). This drug is administered as an intravenous injection.

PW144745

Pw144745 View Pathway
drug action

Clofarabine Drug Metabolism Action Pathway

Homo sapiens

PW144950

Pw144950 View Pathway
drug action

Clofazimine Drug Metabolism Action Pathway

Homo sapiens

PW176008

Pw176008 View Pathway
metabolic

Clofazimine Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Clofazimine are predicted with biotransformer.